EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Denifanstat, a fatty acid synthase inhibitor achieved significant clinical improvement in moderate-to-severe acne vulgaris: a review of mechanistic and clinical data

Julie Harper, Shipra Vinod Gupta, Wen-Wen Tsai, Marie O'Farrel, Andreas Grauer, Jonathan Weiss

SKIN The Journal of Cutaneous Medicine · 10.11.2026 · 10 (6) · s818

DOI: 10.25251/vh2hky50 ↗

Kurz gefasst

Fachartikel in der Zeitschrift SKIN The Journal of Cutaneous Medicine, online erschienen am 10.11.2026. Verfasst von Julie Harper und 5 weiteren Autor:innen. Die Arbeit nennt 4 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Aims:bExcess sebum production via increased de novo lipogenesis (DNL) contributes to acne pathogenesis. Fatty acid synthase (FASN) is the key enzyme in the DNL pathway. Inhibition of FASN reduces sebum production and directly decreases inflammation by disrupting the key inflammatory signaling pathway. Denifanstat (deni), an oral FASN inhibitor, was tested in preclinical models and evaluated for treatment of moderate-to-severe acne in Phase 3 clinical trials in China.

Methods

ASC40-303 (NCT06192264) was a 12-week, randomized, double-blind, placebo (pbo)-controlled Phase 3 trial of deni 50 mg once daily (n=240) vs pbo (n=240) followed by ASC40-304 (NCT06248008) an open-label extension (OLE) in which participants from both arms (n=240) received deni 50 mg through week 52 to assess long-term safety and efficacy. In preclinical studies, primary human cells were isolated from human blood, and sebocytes were Meisen CTCC Hum-280 and SZ95.

Results

Deni directly inhibited DNL and reduced triglyceride production in human sebocyte cell lines. Deni reduced sebum palmitic acid, sapienic acid, and triglycerides in human skin sebum samples collected via non-invasive sebutape. FASN inhibitors also reduced pro-inflammatory cytokine production and decreased Th17 cell development. In ASC40-303, deni met all primary and secondary endpoints and demonstrated significant treatment success (defined as clear or almost clear skin with a ≥2-point IGA improvement) versus pbo (33.2% vs 14.6%; p

Zitieren

APA

Harper, J., Gupta, S. V., Tsai, W., O'Farrel, M., Grauer, A., & Weiss, J. (2026). Denifanstat, a fatty acid synthase inhibitor achieved significant clinical improvement in moderate-to-severe acne vulgaris: a review of mechanistic and clinical data. SKIN The Journal of Cutaneous Medicine, 10(6), s818. https://doi.org/10.25251/vh2hky50

Vancouver

Harper J, Gupta SV, Tsai W, O'Farrel M, Grauer A, Weiss J. Denifanstat, a fatty acid synthase inhibitor achieved significant clinical improvement in moderate-to-severe acne vulgaris: a review of mechanistic and clinical data. SKIN The Journal of Cutaneous Medicine. 2026;10(6):s818. doi:10.25251/vh2hky50

BibTeX
@article{Harper2026,
  author = {Harper, Julie and Gupta, Shipra Vinod and Tsai, Wen-Wen and O'Farrel, Marie and Grauer, Andreas and Weiss, Jonathan},
  title = {Denifanstat, a fatty acid synthase inhibitor achieved significant clinical improvement in moderate-to-severe acne vulgaris: a review of mechanistic and clinical data},
  journal = {SKIN The Journal of Cutaneous Medicine},
  year = {2026},
  volume = {10},
  number = {6},
  pages = {s818},
  doi = {10.25251/vh2hky50}
}
Kostenlos starten →